Palabras claves: covid-19, Multiple Sclerosis, ocrelizumab, pandemic, rituximab
Autores: Carcamo Rodriguez C., Carmisciano L., Ciampi E., Edgar Patricio Correa, Fragoso Y.D., Gomes S., Pimentel M.L.V., Ponzano M., Santos G.A.C., Schiavetti I., Sormani M.P., Steinberg J., Treviño-Frenk I., Vecino M.C.A., Vrech C., Winckler T.C.A.
